Jin Q Cheng

USPTO Granted Patents = 36 (Patent Applications = 12)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 1.7

ph-index = 3

Forward Citations = 39(Granted Patents)

Company Filing History:

33 out of 1,929

University of South Florida

University of Florida Research Foundation, Incorporated

patents

4. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2012-2020

Loading Chart...

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10780104 - Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof (2020-09-22),

2. 10744148 - Methods of treating breast cancer that overexpress AKT kinase (2020-08-18),

3. 10076534 - Effective treatment of ovarian cancer using triciribine and related compounds (2018-09-18),

4. 9896668 - Substrate-mimetic AKT inhibitor (2018-02-20),

5. 9655914 - Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof (2017-05-23),

6. 9518079 - Effective treatment of tumors and cancer with triciribine and related compounds (2016-12-13),

7. 9511084 - Compositions including triciribine and methods of use thereof (2016-12-06),

8. 9498492 - Compositions including triciribine and taxanes and methods of use thereof (2016-11-22),

9. 9486522 - Compositions including triciribine and trastuzumab and methods of use thereof (2016-11-08),

10. 9486492 - Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof (2016-11-08),

11. 9486470 - Compositions including triciribine and one or more platinum compounds and methods of use thereof (2016-11-08),

12. 9457040 - Effective treatment of esophageal adenocarcinoma using triciribine and related compounds (2016-10-04),

13. 9453049 - Substrate-mimetic Akt inhibitor (2016-09-27),

14. 9433635 - Effective treatment of ovarian cancer using triciribine and related compounds (2016-09-06),

15. 9410956 - Micro-RNA profiling in ovarian cancer (2016-08-09),

Title: Inventor Spotlight: Jin Q Cheng - Revolutionizing Cancer Treatment Through Innovation

Introduction:

Meet Jin Q Cheng, a prolific inventor based in Tampa, FL, with a remarkable talent for developing groundbreaking technologies in the field of cancer research. With an impressive portfolio of 36 patents, Cheng has been instrumental in revolutionizing cancer treatment through his innovative inventions.

Latest Patents:

Cheng's latest patents showcase his commitment to advancing combination therapies for the treatment and prevention of tumors, cancer, and other cell proliferation disorders. One of his notable inventions includes compositions combining triciribine and epidermal growth factor receptor inhibitor compounds for more targeted and effective cancer treatments, particularly in breast cancer cases where AKT kinase is overexpressed.

Career Highlights:

Throughout his career, Cheng has made significant contributions to the field of oncology through his work at esteemed institutions such as the University of South Florida and Yale University. His dedication to developing safer and more potent treatment options for cancer patients has earned him recognition as a leader in the field of cancer research.

Collaborations:

In his collaborative efforts, Cheng has had the privilege of working alongside respected professionals in the industry, including Said M Sebti and Andrew D Hamilton. These partnerships have enabled Cheng to leverage diverse expertise and innovate more effectively in the pursuit of novel cancer therapies.

Conclusion:

In conclusion, Jin Q Cheng stands as a beacon of innovation in the fight against cancer, with his groundbreaking inventions paving the way for more effective and targeted treatment options. His relentless pursuit of advancements in cancer therapy highlights the transformative power of innovation in improving patient outcomes and quality of life.

This text is generated by artificial intelligence and may not be accurate.